1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paclitaxel Injection Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Paclitaxel Injection Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pricing Analysis
5.2. Diseases Prevalence & Incidence Rate Globally and with the Key Countries
5.3. Covid-19 Pandemic Impact on the Industry
6. Global Paclitaxel Injection Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Application, 2017-2031
6.3.1. Ovarian Carcinoma
6.3.2. Breast Carcinoma
6.3.3. Pancreatic Cancer
6.3.4. Advanced Non-small Cell Lung Carcinoma
6.3.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
6.4. Market Attractiveness Analysis, by Application
7. Global Paclitaxel Injection Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017-2031
7.3.1. Hospital Pharmacies
7.3.2. Online Pharmacies
7.3.3. Retail Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Paclitaxel Injection Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Paclitaxel Injection Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Application, 2017-2031
9.2.1. Ovarian Carcinoma
9.2.2. Breast Carcinoma
9.2.3. Pancreatic Cancer
9.2.4. Advanced Non-small Cell Lung Carcinoma
9.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Retail Pharmacies
9.4. Market Value Forecast, by Country, 2017-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Application
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Paclitaxel Injection Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Application, 2017-2031
10.2.1. Ovarian Carcinoma
10.2.2. Breast Carcinoma
10.2.3. Pancreatic Cancer
10.2.4. Advanced Non-small Cell Lung Carcinoma
10.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Hospital Pharmacies
10.3.2. Online Pharmacies
10.3.3. Retail Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Application
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Paclitaxel Injection Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Application, 2017-2031
11.2.1. Ovarian Carcinoma
11.2.2. Breast Carcinoma
11.2.3. Pancreatic Cancer
11.2.4. Advanced Non-small Cell Lung Carcinoma
11.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Application
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Paclitaxel Injection Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Application, 2017-2031
12.2.1. Ovarian Carcinoma
12.2.2. Breast Carcinoma
12.2.3. Pancreatic Cancer
12.2.4. Advanced Non-small Cell Lung Carcinoma
12.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
12.3. Market Value Forecast, by Distribution Channel, 2017-2031
12.3.1. Hospital Pharmacies
12.3.2. Online Pharmacies
12.3.3. Retail Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Application
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Paclitaxel Injection Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Application, 2017-2031
13.2.1. Ovarian Carcinoma
13.2.2. Breast Carcinoma
13.2.3. Pancreatic Cancer
13.2.4. Advanced Non-small Cell Lung Carcinoma
13.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
13.3. Market Value Forecast, by Distribution Channel, 2017-2031
13.3.1. Hospital Pharmacies
13.3.2. Online Pharmacies
13.3.3. Retail Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Application
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Accord Healthcare Ireland Ltd.
14.3.1.1. Company Overview
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Business Strategies
14.3.1.5. Recent Developments
14.3.2. Alembic Pharmaceuticals Limited
14.3.2.1. Company Overview
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. Business Strategies
14.3.2.5. Recent Developments
14.3.3. American Regent, Inc.
14.3.3.1. Company Overview
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. Business Strategies
14.3.3.5. Recent Developments
14.3.4. Dash Pharmaceuticals LLC
14.3.4.1. Company Overview
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. Business Strategies
14.3.4.5. Recent Developments
14.3.5. Dr. Reddy’s Laboratories Ltd.
14.3.5.1. Company Overview
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. Business Strategies
14.3.5.5. Recent Developments
14.3.6. Fresenius Kabi India Pvt. Ltd.
14.3.6.1. Company Overview
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. Business Strategies
14.3.6.5. Recent Developments
14.3.7. Gland Pharma Limited
14.3.7.1. Company Overview
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. Business Strategies
14.3.7.5. Recent Developments
14.3.8. Heter
14.3.8.1. Company Overview
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. Business Strategies
14.3.8.5. Recent Developments
14.3.9. Intas Pharmaceuticals Ltd.
14.3.9.1. Company Overview
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. Business Strategies
14.3.9.5. Recent Developments
14.3.10. MSN Laboratories
14.3.10.1. Company Overview
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. Business Strategies
14.3.10.5. Recent Developments
14.3.11. Panacea Biotec
14.3.11.1. Company Overview
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. Business Strategies
14.3.11.5. Recent Developments
14.3.12. Pfizer, Inc.
14.3.12.1. Company Overview
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. Business Strategies
14.3.12.5. Recent Developments
14.3.13. Sandoz International GmbH
14.3.13.1. Company Overview
14.3.13.2. Financial Overview
14.3.13.3. Product Portfolio
14.3.13.4. Business Strategies
14.3.13.5. Recent Developments
14.3.14. Teva Pharmaceutical Industries Ltd.
14.3.14.1. Company Overview
14.3.14.2. Financial Overview
14.3.14.3. Product Portfolio
14.3.14.4. Business Strategies
14.3.14.5. Recent Developments
14.3.15. Zydus Group
14.3.15.1. Company Overview
14.3.15.2. Financial Overview
14.3.15.3. Product Portfolio
14.3.15.4. Business Strategies
14.3.15.5. Recent Developments
14.3.16. Apotex Corp.
14.3.16.1. Company Overview
14.3.16.2. Financial Overview
14.3.16.3. Product Portfolio
14.3.16.4. Business Strategies
14.3.16.5. Recent Developments
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/